One To Watch: Chi-Med Approaches Inflection Points

Hutchison China MediTech, or Chi-Med, will report pivotal or proof of concept data for savolitinib, fruquintinib and two other tyrosine kinase inhibitor candidates by Q1 2017. Having built a global cancer and inflammation R&D pipeline on the back of what started out 16 years ago as a domestic commercial botanicals business based in China, Chi-Med is now one to watch.